Jesus Navarro, MD
Nephrology · Tampa, FLNPI 1689662462
Payments from drug & device makers
Across 2,443 payments — averaging $5425.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$4M
- Pfizer$3.4M
- Vertex$1.2M
- Merck$701K
- Akebia Therapeutics Inc$690K
- United Therapeutics Corporation$600K
- plus $2.6M from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $4,006,336 |
| Pfizer | 208 | $3,371,622 |
| Vertex | 10 | $1,247,950 |
| Merck | 14 | $701,113 |
| Akebia Therapeutics Inc | 1,878 | $689,788 |
| United Therapeutics Corporation | 16 | $600,269 |
| OPKO Pharmaceuticals, LLC | 60 | $375,573 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $301,621 |
| Novartis | 17 | $288,742 |
| Amgen(2 entities) | 19 | $248,864 |
| Eli Lilly | 1 | $213,216 |
| F. Hoffmann-la Roche AG | 6 | $208,758 |
| CSL Behring | 61 | $157,121 |
| GSK | 47 | $142,272 |
| Braintree Laboratories, Inc. | 10 | $137,495 |
| Astrazeneca UK Limited | 12 | $115,476 |
| Gilead | 14 | $98,288 |
| Insmed, Inc. | 5 | $64,376 |
| AstraZeneca | 4 | $58,842 |
| Sanofi US Services Inc. | 12 | $52,556 |
| Boehringer Ingelheim | 3 | $45,678 |
| Bayer | 17 | $33,748 |
| Janssen Research & Development, LLC | 1 | $26,200 |
| Kadmon Corporation LLC | 5 | $25,775 |
| Biogen | 1 | $15,334 |
| Genentech, Inc. | 4 | $13,900 |
| Madrigal Pharmaceuticals | 1 | $8,201 |
| Bristol Myers Squibb | 1 | $6,209 |
| Vifor Pharma, Inc. | 4 | $85 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $80 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Aurinia Pharma U.S., Inc. | 2 | $35 |
| Fresenius USA Marketing, Inc. | 1 | $16 |
How this compares
$13,255,586 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Tampa
- Cecilio HernandezTampa$609K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
- Jorge PosadaCoral Gables$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.